148 related articles for article (PubMed ID: 34924127)
1. L-type amino acid transporter 1 as a target for inflammatory disease and cancer immunotherapy.
Hayashi K; Anzai N
J Pharmacol Sci; 2022 Jan; 148(1):31-40. PubMed ID: 34924127
[TBL] [Abstract][Full Text] [Related]
2. Targeting L-type amino acid transporter 1 in innate and adaptive T cells efficiently controls skin inflammation.
Cibrian D; Castillo-González R; Fernández-Gallego N; de la Fuente H; Jorge I; Saiz ML; Punzón C; Ramírez-Huesca M; Vicente-Manzanares M; Fresno M; Daudén E; Fraga-Fernandez J; Vazquez J; Aragonés J; Sánchez-Madrid F
J Allergy Clin Immunol; 2020 Jan; 145(1):199-214.e11. PubMed ID: 31605740
[TBL] [Abstract][Full Text] [Related]
3. L-type Amino Acid Transporter 1 as a Therapeutic Target in Pancreatic Cancer.
Norrsell R; Bauden M; Andersson R; Ansari D
Cancer Control; 2024; 31():10732748241251583. PubMed ID: 38683590
[TBL] [Abstract][Full Text] [Related]
4. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
Nachef M; Ali AK; Almutairi SM; Lee SH
Front Immunol; 2021; 12():624324. PubMed ID: 33953707
[TBL] [Abstract][Full Text] [Related]
5. [Drug Discovery Targeting an Amino Acid Transporter for Diagnosis and Therapy].
Wiriyasermkul P; Moriyama S; Kongpracha P; Nagamori S
Yakugaku Zasshi; 2021; 141(4):501-510. PubMed ID: 33790117
[TBL] [Abstract][Full Text] [Related]
6. Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapy.
Ohkawa M; Ohno Y; Masuko K; Takeuchi A; Suda K; Kubo A; Kawahara R; Okazaki S; Tanaka T; Saya H; Seki M; Enomoto T; Yagi H; Hashimoto Y; Masuko T
Biochem Biophys Res Commun; 2011 Mar; 406(4):649-55. PubMed ID: 21371427
[TBL] [Abstract][Full Text] [Related]
7. LAT1 is a critical transporter of essential amino acids for immune reactions in activated human T cells.
Hayashi K; Jutabha P; Endou H; Sagara H; Anzai N
J Immunol; 2013 Oct; 191(8):4080-5. PubMed ID: 24038088
[TBL] [Abstract][Full Text] [Related]
8. L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism.
Sato M; Harada-Shoji N; Toyohara T; Soga T; Itoh M; Miyashita M; Tada H; Amari M; Anzai N; Furumoto S; Abe T; Suzuki T; Ishida T; Sasano H
Sci Rep; 2021 Jan; 11(1):589. PubMed ID: 33436954
[No Abstract] [Full Text] [Related]
9. The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells.
Kim CH; Park KJ; Park JR; Kanai Y; Endou H; Park JC; Kim DK
Anticancer Res; 2006; 26(4B):2943-8. PubMed ID: 16886618
[TBL] [Abstract][Full Text] [Related]
10. The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer.
Lu X
Curr Cancer Drug Targets; 2019; 19(11):863-876. PubMed ID: 31376820
[TBL] [Abstract][Full Text] [Related]
11. c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells.
Hayashi K; Jutabha P; Endou H; Anzai N
Oncol Rep; 2012 Sep; 28(3):862-6. PubMed ID: 22736142
[TBL] [Abstract][Full Text] [Related]
12. The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer.
Salisbury TB; Arthur S
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103560
[TBL] [Abstract][Full Text] [Related]
13. PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (x
Krys D; Mattingly S; Glubrecht D; Wuest M; Wuest F
Mol Imaging Biol; 2020 Dec; 22(6):1562-1571. PubMed ID: 32789819
[TBL] [Abstract][Full Text] [Related]
14. Hemocompatible LAT1-inhibitor can induce apoptosis in cancer cells without affecting brain amino acid homeostasis.
Markowicz-Piasecka M; Huttunen J; Montaser A; Huttunen KM
Apoptosis; 2020 Jun; 25(5-6):426-440. PubMed ID: 32405891
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of L-Type Amino Acid Transporter 1 (LAT1) in Various Cancers: A Meta-Analysis.
Zhang C; Xu J; Xue S; Ye J
Mol Diagn Ther; 2020 Oct; 24(5):523-536. PubMed ID: 32410110
[TBL] [Abstract][Full Text] [Related]
16. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors.
Fan X; Ross DD; Arakawa H; Ganapathy V; Tamai I; Nakanishi T
Biochem Pharmacol; 2010 Sep; 80(6):811-8. PubMed ID: 20510678
[TBL] [Abstract][Full Text] [Related]
17. The L-Type Amino Acid Transporter LAT1-An Emerging Target in Cancer.
Häfliger P; Charles RP
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100853
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling.
Nagamori S; Wiriyasermkul P; Okuda S; Kojima N; Hari Y; Kiyonaka S; Mori Y; Tominaga H; Ohgaki R; Kanai Y
Amino Acids; 2016 Apr; 48(4):1045-1058. PubMed ID: 26724922
[TBL] [Abstract][Full Text] [Related]
19. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation.
Quan L; Ohgaki R; Hara S; Okuda S; Wei L; Okanishi H; Nagamori S; Endou H; Kanai Y
J Exp Clin Cancer Res; 2020 Nov; 39(1):266. PubMed ID: 33256804
[TBL] [Abstract][Full Text] [Related]
20. Expression of large neutral amino acid transporters LAT1 and LAT2 in medulloblastoma.
Cicone F; Minniti G; Oliva MA; Carideo L; Prior JO; Scopinaro F; Giangaspero F; Arcella A
Brain Tumor Pathol; 2017 Oct; 34(4):179-181. PubMed ID: 28815339
[No Abstract] [Full Text] [Related]
[Next] [New Search]
